Abstract
Purpose
To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab trial (NCT00418574).
Methods
The study included 129 patients, 91 in the abagovomab arm and 38 in the placebo arm. Circulating CA125-specific cytotoxic T lymphocytes (CTL) were measured by a flow cytometry-based interferon-γ producing assay. Human antimouse antibody and anti-anti-idiotypic (Ab3) were assessed by ELISA. Patients were evaluated before starting the treatment and at different time points during induction and maintenance phases.
Results
A similar percentage of patients in both the placebo and abagovomab arms had CA125-specific CTL (26.3 and 31.8 %, respectively; p = 0.673 by Fisher’s exact test). Patients with CA125-specific CTL in both arms tended to have an increased relapse-free survival (RFS, log-rank test p = 0.095) compared to patients without. Patients (n = 27) in the abagovomab arm without CA125-specific CTL but that developed Ab3 above the cutoff (defined as median Ab3 level at week 22) had a prolonged RFS compared to patients (n = 24) that did not develop Ab3 above the cutoff (log-rank test p = 0.019).
Conclusion
Abagovomab does not induce CA125-specific CTL. However, patients with CA125-specific CTL perform better than patients without, irrespective of abagovomab treatment. Abagovomab-induced Ab3 associate with prolonged RFS in patients without CA125-specific CTL. Further studies are needed to confirm these data and to assess the potential utility of these immunological findings as a tool for patient selection in clinical trial.
Similar content being viewed by others
Abbreviations
- Ab3:
-
Anti-anti-idiotypic
- Anti-Id:
-
Anti-idiotypic
- CTL:
-
Cytotoxic T lymphocytes
- ECD:
-
Proprietary name for Texas Red-conjugated phycoerythrin
- FITC:
-
Fluorescein
- HAMA:
-
Human antimouse antibody
- IFN:
-
Interferon
- mAb:
-
Monoclonal antibody
- MIATA:
-
Minimal information about T cell assays
- MIMOSA:
-
Monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab
- OC:
-
Ovarian cancer
- PE:
-
Phycoerythrin
- PeCy5:
-
Cy5-conjugated phycoerythrin
- PMT:
-
Photomultiplier tube
- RFS:
-
Relapse free survival
- SEB:
-
Staphylococcal Enterotoxin B
References
Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res 2:13. doi:10.1186/1757-2215-2-13
Legge F, Paglia A, D’Asta M, Fuoco G, Scambia G, Ferrandina G (2011) Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 11:214. doi:10.1186/1471-2407-11-214
Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529
Ziebarth AJ, Landen CN, Alvarez RD (2012) Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 55:156–172
Miyake TM, Sood AK, Coleman RL (2013) Contemporary use of Bevacizumab in ovarian cancer. Exp Opin Biol Ther 13:283–294
Liu JF, Konstantinopoulos PA, Matulonis UA (2014) PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol. doi:10.1016/j.ygyno.2014.02.039
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213
Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF (2004) Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507–3516
Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G (1993) Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 12:583–589
Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF (2003) Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 189:28–36
Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF (2004) CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94:340–351
Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M (2009) The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32:54–65
Jerne NK (1974) Towards a network theory of the immune system. Ann immunol 125C(1–2):373–389
Gómez RE, Ardigo ML (2012) Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective. Front Oncol 2:147. doi:10.3389/fonc.2012.00147
Schlebusch H, Wagner U, Grünn U, Schultes BA (1995) Monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 14:167–174
Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10:1580–1587
Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F (2006) The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 17:1568–1577
Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K (2006) Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12:5503–5510
Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a Phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study. J Clin Oncol 31:1554–1561
Waldrop SL, Davis KA, Maino VC, Picker LJ (1998) Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 161:5284–5295
Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, Scambia G (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418–1428
Campoli M, Ferris R, Ferrone S, Wang X (2010) Immunotherapy of malignant disease with tumor antigen (TA)- specific monoclonal antibodies: does its therapeutic efficacy require cooperation with TA-specific CTL? Clin Cancer Res 16:11–20
Acknowledgments
HAMA and Ab3 data were provided by Menarini Ricerche, Pomezia, Italy.
Conflict of interest
Part of reagents (e.g., mAbs, CA125, staining buffers, etc.) and disposables (plasticwares) have been provided by Menarini Ricerche, Pomezia, Italy. The authors declare they have no financial or other interest that is relevant to the subject matter under consideration in this article with Menarini Ricerche.
Author information
Authors and Affiliations
Corresponding author
Additional information
Marco Fossati and Alexia Buzzonetti have contributed equally to this work.
Andrea Fattorossi and Alessandra Battaglia are joint senior authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Buzzonetti, A., Fossati, M., Catzola, V. et al. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial. Cancer Immunol Immunother 63, 1037–1045 (2014). https://doi.org/10.1007/s00262-014-1569-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-014-1569-0